CHARACTERISTICS OF THE PRODUCT
Welltuss-K is the response to the need for a product with alcohol concentration lower than 1% so that it can be used also for children. It is not the younger brother of its predecessor: indeed, it represents an evolution, creating a synergy with Lapacho to draw on his formidable treasure of flavonoids, coenzyme Q50, saponins, Carnosol, mineral salts, trace elements and Tannins such as catechins and Lapachol, which brings together one of the most bioavailable natural systems of active ingredients for the body’s natural defenses.
The Welltuss-K syrup is prepared from a handmade and patented processing technique. Through several macerations, processing of the capsule and grinding at the mortar, under the constant supervision of experts, many more active ingredients – 90 % more – are obtained than in industrial production. Every ingredient used – Boswellia for example – is important not only for its therapeutic value but also for the benefits of a true Phyto complex in its active phase. The roots of a fresh plant of Althea officinalis have a beneficial effect on the function of the mucous membranes of the respiratory system and the well-being of the throat.
The various essences, the extracts, the macerated products and the precious derivatives from the embryonic tissue of fresh buds act and interact so that the body better responds to external stress. All this and more. In a landscape of mass industrial products Welltuss-K with extract of Lapacho is a unique and precious product.
Wellbeing of airways
- ALTEA OFFICINALIS fresh plant root
- BOSWELLIA SERRATA E.F. resin (incense) titrated at 65% in Boswellic Acid*
- LAPACHO TABEBUIA AVELLANEDAE LORENZ CORTEX dry extract
- JUGLANS REGIA Fresh buds, glyceric macerate
- TOLU BALSAM Fluid Extract
HOW TO USE IT
15 ml 3 times a day to exploit the effects of mucilage and tannins. Do not drink or eat for 20 minutes after taking the syrup.
Althea 5000 mg
Tabebuia 1090 mg
Tolu Balsam 500 mg
Macerated Walnut 210 mg
Boswellia 150 mg
200 ml – 250 g
Glass bottle, sealed cap and small glass
*country origin China
Choi WH, Um MY, Ahn J, et al. Ethanolic extract of Taheebo attenuates increase in body weight and fatty liver in mice fed a highfat diet. Molecules. 2014 Oct 8; 19 (10): 16013-23
Suo, Maorong & Ohta, Tomihisa & Takano, Fumihide & Jin, Shouwen. (2013). Bioactive Phenylpropanoid Glycosides from Tabebuia avellanedae. Molecules (Basel, Switzerland). 18. 7336-7345. 10.3390/molecules18077336.
Taylor L., Lapacho. In: The healing power of rainforest herbs, Ed. Square One Publishers Ny. (2005)
Natacha V., et al., 2-phenil-lapachone can affect mitocondrial function by radox cycling madiated oxidation, Arch. Biochem. Biophiys, 432, 129-135 (2004)
Awale S. et al., Nitric Oxide (NO) production inhibitory constituents of Tabebuia avellanadae from Brazil, Chem. Pharm. Bull, Tokio, 53, 710-713 (jun 2005)
Byeon SE, Chung JY, Lee YG,et al. In vitro and in vivo antiinflammatory effects of taheebo, a water extract from the inner bark of Tabebuia avellanedae. J Ethnopharmacol. 2008 Sep 2; 119 (1): 145- 52.
Anon (CSIR). The Wealth of India, Raw Materials, Vol. 1, New Delhi: Council of Scientific and Industrial Research; 1948
Felter H, Lloyd J. Kings American Dispensatory, Vols. I and II, Cincinnati: Ohio Valley Company, US, 1898.
Sharma RA, Verma KC. Studies on gum obtained from Boswellia serrata Roxb. Indian Drugs 1980;17:225.
Sharma S, Thawani V, Hingorani L. Pharmacokinetic study of 11-ketobeta-boswellic acid. Phytomedicine 2004;11:255-60.
Siemoneit U, Pergola C, Jazzar B, Northoff H, Skarke C, Jauch J, et al. On the interference of boswellic acids with 5-lipoxygenase: Mechanistic studies in vitro and pharmacological relevance. Eur J Pharmacol 2009;606:246-54
Devi VK, Jain N, Valli KS. Importance of novel drug delivery systems in herbal medicines. Phcog Rev. 2010; 4(7): 27–31p.
Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, Ammon HPT (1998) Effects of Boswellia serrata gum resin in patients with bronchial asthma: Results of a double- blind, placebo-controlled, 6-week clinical study. Eur J Med Res 3: 511–514